258 related articles for article (PubMed ID: 21709817)
1. Clinical epidemiology and pharmacology of CYP2D6 inhibition related to breast cancer outcomes.
Cronin-Fenton DP; Lash TL
Expert Rev Clin Pharmacol; 2011 May; 4(3):363-77. PubMed ID: 21709817
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.
Cronin-Fenton DP; Damkier P; Lash TL
Future Oncol; 2014 Jan; 10(1):107-22. PubMed ID: 24328412
[TBL] [Abstract][Full Text] [Related]
3. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.
Ahern TP; Pedersen L; Cronin-Fenton DP; Sørensen HT; Lash TL
Cancer Epidemiol Biomarkers Prev; 2009 Sep; 18(9):2562-4. PubMed ID: 19690182
[TBL] [Abstract][Full Text] [Related]
4. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
5. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
[TBL] [Abstract][Full Text] [Related]
6. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.
Dezentjé VO; van Blijderveen NJ; Gelderblom H; Putter H; van Herk-Sukel MP; Casparie MK; Egberts AC; Nortier JW; Guchelaar HJ
J Clin Oncol; 2010 May; 28(14):2423-9. PubMed ID: 20385997
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
8. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer.
Lammers LA; Mathijssen RH; van Gelder T; Bijl MJ; de Graan AJ; Seynaeve C; van Fessem MA; Berns EM; Vulto AG; van Schaik RH
Br J Cancer; 2010 Sep; 103(6):765-71. PubMed ID: 20700120
[TBL] [Abstract][Full Text] [Related]
9. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
Seruga B; Amir E
Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
[TBL] [Abstract][Full Text] [Related]
13. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Singh MS; Francis PA; Michael M
Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
Punglia RS; Burstein HJ; Winer EP; Weeks JC
J Natl Cancer Inst; 2008 May; 100(9):642-8. PubMed ID: 18445827
[TBL] [Abstract][Full Text] [Related]
16. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen and CYP2D6: a contradiction of data.
Hertz DL; McLeod HL; Irvin WJ
Oncologist; 2012; 17(5):620-30. PubMed ID: 22531359
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Goetz MP; Kamal A; Ames MM
Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
[TBL] [Abstract][Full Text] [Related]
20. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]